U.S. Markets closed

Atossa Genetics Inc. (ATOS)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.45-0.02 (-3.27%)
At close: 4:00PM EDT
People also watch
BIOCAPRISGNLAVEOCAPN
Interactive chart
Previous Close0.47
Open0.46
Bid0.00 x
Ask0.00 x
Day's Range0.44 - 0.55
52 Week Range0.40 - 5.55
Volume412,148
Avg. Volume228,282
Market Cap3.34M
Beta2.00
PE Ratio (TTM)-0.21
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals2 months ago

    Seattle breast cancer company stock plummets as it seeks funding to continue operations

    Atossa Genetics stock fell 27.5 percent after the company announced plans to raise $4.6 million in an underwritten public offering on Tuesday. The Seattle biotech company declined to comment during the stock offering period. Atossa develops drugs and medical devices that treat breast cancer and other breast conditions.

  • Zacks Small Cap Research2 months ago

    ATOS: Pure Player in the Breast Care Space

    On Jan 9, 2017, Atossa (ATOS) announced that it is transferring the site of its Phase II study of fulvestrant administered with its patented microcatheters in patients with ductal carcinoma in situ or breast cancer who are scheduled for lumpectomy or mastectomy. The study was initiated at Columbia University Medical Center Breast Cancer Programs (New York) and is now being transferred to Montefiore Medical Center in New York. This move comes about as the principal investigator, Dr. Sheldon M. Feldman, M.D., has relocated to Montefiore and is now Chief, Division of Breast Surgery & Breast Surgical Oncology, Director, Breast Cancer Services, and Professor, Department of Surgery, at the Montefiore Medical Center, The University Hospital for the Albert Einstein College of Medicine, Montefiore Einstein Center for Cancer Care.

  • Zacks Small Cap Researchlast year

    ATOS: Focus on Therapeutics post the sale of Diagnostics Business

    For the year ended December 31, 2015, substantially all of the revenue we recognized consisted of pharmacogenomics testing by the NRLBH. As a result of the sale of the NRLBH, the revenue and cost of revenue is presented as discontinued operations for both years ended 2015 and 2014. The NLRBH had a total net revenue of $5.5 million for the year ended December 31, 2015 consisting of mainly pharmacogenomics testing.